首页> 外国专利> COMPOSITION OF FENTANYL CITRATE ORAL SOLID TRANSMUCOSAL DOSAGE FORM, DEXTROSE MONOHYDRATE AS MAJOR EXCIPIENT AND BINDING MATERIAL THEREFOR AND METHODS OF PRODUCING THEM

COMPOSITION OF FENTANYL CITRATE ORAL SOLID TRANSMUCOSAL DOSAGE FORM, DEXTROSE MONOHYDRATE AS MAJOR EXCIPIENT AND BINDING MATERIAL THEREFOR AND METHODS OF PRODUCING THEM

机译:芬太尼枸O酸口服固体经皮给药剂型,作为主要赋形剂的一水合右旋糖酐的组成及其结合方法和制备方法

摘要

A process of preparing a highly uniform oral transmucosal lozenge of fentanyl citrate (a "fentanyl lollipop") provides uniform distribution of the drug. The content uniformity between the lozenges and uniform distribution of the drug within a lozenge is achieved by dry mixing a micronized drug of a particle size of about one to ten microns with at least one major excipient, such as a dextrose, having cavities and pores on its surface after pressing into the lozenge shape. The major component of the lozenge can be a binding material prepared with a mixture of dextrose hydrate, food grade starch and water. This binding material has better strength to bind the stick to the lozenge due to stronger cross-linked matrix formation between the lozenge and the binding material.
机译:制备柠檬酸芬太尼(“芬太尼棒棒糖”)的高度均匀的口服透粘膜锭剂的方法提供了药物的均匀分布。锭剂之间的含量均匀性和锭剂中药物的均匀分布是通过将粒径约为1到10微米的微粉化药物与至少一种主要的赋形剂(如葡萄糖)干混而形成的,该赋形剂上有空腔压成菱形后的表面。锭剂的主要成分可以是用葡萄糖水合物,食品级淀粉和水的混合物制备的粘合材料。由于在锭剂和结合材料之间更强的交联基质形成,该结合材料具有更好的强度以将棒结合到锭剂。

著录项

  • 公开/公告号EP1959924A2

    专利类型

  • 公开/公告日2008-08-27

    原文格式PDF

  • 申请/专利权人 NAVINTA LLC.;

    申请/专利号EP20060837296

  • 申请日2006-11-10

  • 分类号A61K9;A61K9/20;A61K9/36;A61K9/22;

  • 国家 EP

  • 入库时间 2022-08-21 19:55:22

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号